STAT+: New startup to develop a GLP-1 drug for addiction
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A new startup focused on GLP-1 drugs launched today, but unlike the dozens of other GLP-1 companies, this one isn’t studying weight loss. The need-to-know this morning Roche plans to launch Phase […]
Where Will Eli Lilly Be in 10 Years?
Key Points The pharmaceutical industry has a well-structured cycle. Eli Lilly is currently benefiting from the early stages of the cycle. In 10 years, if not sooner, investors will begin to worry about Eli Lilly’s future beyond GLP-1 drugs. 10 stocks we like better than Eli Lilly › If you follow the news at all, […]
Do GLP-1s Have Deleterious Effects on Muscle?
Emerging evidence suggests that GLP-1 receptor agonists may improve muscle quality as body weight and lean mass decline. Medscape Gastroenterology
Roche, trailing in obesity, showcases new data for GLP-1 shot
A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to […]
STAT+: Pharmalittle: We’re reading about a Roche obesity drug, a clash over 340B claims data, and more
Hello, everyone, and how are you today? We are just fine, thank you, despite the frigid temperature and cold winds wafting across the Pharmalot campus, where our official mascots are, thankfully, snoozing away in a nearby corner. As for us, we are going about our usual business — foraging for interesting and saucy items, and […]
Women On Menopause Hormone Therapy Lose More Weight With Zepbound, Study Finds
TUESDAY, Jan. 27, 2026 — Good news for women taking hormone therapy for menopause: You might find that weight-loss drugs are more effective.
Women on hormone therapy lost 35% more weight while taking Zepbound (tirzepatide), researchers…
STAT+: Roche moves obesity drug to pivotal trials after mid-stage success
Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after reporting Tuesday that the drug led to significant weight loss in a mid-stage trial. The drug, known as CT-388, led to a placebo-adjusted weight loss of 18.3% after 48 weeks in the Phase 2 trial at the highest dose tested […]
One-shot weight loss: Can gene therapy actually replace the GLP-1 revolution?
Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to produce its own GLP-1 hormone naturally.
Why exercise is essential for restoring fitness after GLP-1-based weight loss
This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, improves physical function and cardiorespiratory fitness after diet-induced weight loss in adults with obesity. In contrast, liraglutide alone sustains weight loss but does not significantly improve measured physical fitness outcomes.